

Liste der bewilligten Forschungsprojekte 2026 *Liste des projets de recherche acceptés en 2026*

Basic research

Ablasser Andrea | [In vivo adjuvanted CAR immune cells for solid tumors](#)
Global Health Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne
CHF 374 995 | 36 months | KFS-6628-02-2026

Aceto Nicola | [Identification of intravasation hotspots in pancreatic cancer](#)
Department of Biology, Eidgenössische Technische Hochschule Zürich (ETHZ), Zürich
CHF 369 522 | 36 months | KFS-6627-02-2026

Ahmed Daniel | [In Vivo Vessel-Targeted BBB/BBTB Opening and Intratumoral Drug Delivery in Glioblastoma Using Ultrasound-Steerable Microrobots](#)
Faculty of Medicine /ARTORG Center for Biomedical Engineering Research, Universität Bern (UniBE), Bern
CHF 372 897 | 36 months | KFS-6729-02-2026

Bodenmiller Bernd | [Discovering therapeutic vulnerabilities of breast cancer cellular phenotypes](#)
Department of Quantitative Biomedicine, Institute for Molecular Health Science, Universität Zürich (UZH), Zurich
CHF 375 000 | 36 months | KFS-6674-02-2026-R

Böttcher Steffen | [Dissecting and targeting of the immune microenvironment in TP53-mutant acute myeloid leukemia in the steady state and during CAR T cell therapy](#)
Department of Medical Oncology and Hematology, Universitätsspital Zürich (USZ), Zürich
CHF 371 096 | 48 months | KFS-6707-02-2026-R

Gentner Bernhard | [Precision co-engineering of novel IL1RAP-CAR-T cells and an IL1RAP-protected hypo-inflammatory hematopoietic system for AML treatment](#)
Department of Oncology UNIL-CHUV, Centre hospitalier universitaire vaudois (CHUV), Lausanne
CHF 375 000 | 36 months | KFS-6667-02-2026

Gfeller David | [Deciphering key determinants of TCR cross-reactivity in cancer epitope recognition](#)
Ludwig Institute for Cancer Research, Université de Lausanne (UNIL), Lausanne
CHF 372 060 | 36 months | KFS-6602-02-2026-R

Khanna Nina | Patient-centered discovery of EBV-specific T cell receptors in EBV-associated malignancies for precision immunotherapy
Biomedicine and Division of Infectious diseases, Universität Basel, Basel
CHF 356 397 | 48 months | KFS-6690-02-2026

Limongelli Vittorio | Rewiring chemokine signaling to overcome antagonist tolerance in CXCR4-mutated lymphoid malignancies.
Faculty of Biomedical Sciences, Università della Svizzera italiana (USI), Lugano
CHF 374 916 | 36 months | KFS-6697-02-2026

Monticelli Silvia | Rewiring RNA-binding protein circuits for enhanced anti-tumor CAR-T cell efficacy
Molecular Immunology Lab, Istituto di Ricerca in Biomedicina (IRB), Bellinzona
CHF 374 870 | 48 months | KFS-6603-02-2026

Rottenberg Sven | Spatiotemporal tracking of residual disease and recurrence in BRCA1-deficient breast cancer models
Department for Infectious Diseases and Pathobiology, Universität Bern (UniBE), Bern
CHF 375 000 | 48 months | KFS-6661-02-2026

Simonetta Federico | Safe-T-reg: a tolerogenic niche for T-reg expansion and activation to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Division of Hematology, Department of Oncology, Hôpitaux universitaires de Genève (HUG), Geneva
CHF 373 950 | 36 months | KFS-6648-02-2026

Stockmann Christian | Harnessing the coevolution of the immunopeptidome of tumor cells and stromal fibroblasts in pancreatic ductal adenocarcinoma
Institute of Anatomy, Universität Zürich (UZH), Zurich
CHF 373 828 | 36 months | KFS-6612-02-2026-R

Vozenin Marie-Catherine | WHALE – WHAT are the Molecular Determinants of the FLASH Effect: a primary role for cebpb/fatty acid oxidation pathway and cell cycle in zebrafish embryos after FLASH irradiation.
Service de Radio-Oncologie, Hôpitaux universitaires de Genève (HUG), Geneva
CHF 362 132 | 36 months | KFS-6622-02-2026

Zaugg Judith | Heterogeneous bone marrow niches shape leukemic persistence and relapse in acute myeloid leukemia
Department of Biomedicine, Universität Basel, Basel
CHF 345 120 | 36 months | KFS-6698-02-2026

Clinical Research – laboratory-oriented

de Leval Laurence | Spatial profiling of intestinal T-cell lymphomas

Department of Laboratory Medicine and Pathology, Centre hospitalier universitaire vaudois (CHUV), Lausanne

CHF 375 000 | 36 months | KFS-6652-02-2026-R

Grewe Benjamin | Real-Time Label-Free Tumor Detection Algorithm for Intraoperative Sampling to Improve Surgical Precision

EE, Institute of Neuroinformatics, Eidgenössische Technische Hochschule Zürich (ETHZ), Zurich

CHF 244 052 | 24 months | KFS-6666-02-2026-R

Heim Markus Hermann | Personalized Treatment for Liver Cancer

Gastroenterologie/Hepatology, Clarunis AG, Basel

CHF 250 000 | 24 months | KFS-6660-02-2026-R

Jandus Camilla | Targeting tumor-derived steroids to restore NK cell functions in ovarian cancer patients

Department of Pathology and Immunology, PATIM, Université de Genève (UNIGE), Geneva

4
CHF 369 509 | 36 months | KFS-6688-02-2026

Kreutmair Stefanie | Dissecting Antigen-Specific and Relapse-Associated Immune Signatures in First-in-Human WT1 Recombinant Protein Vaccinated AML Patients

Institute of Experimental Immunology, Universität Zürich (UZH), Zurich

CHF 360 183 | 48 months | KFS-6706-02-2026-R

Morscher Raphael Johannes | Personalized Targeting of Oncogene-Driven Folate Metabolism

Department für Onkologie, Hämatologie und Zelluläre Therapien, Universitäts-Kinderspital Zürich, Zürich

CHF 362 447 | 36 months | KFS-6715-02-2026

Radpour Ramin | Molecular profiling of immune signatures and cellular interactions in human leukemia stem cells and paired B cell subsets in AML

Department for BioMedical Research (DBMR), Universität Bern (UniBE), Bern

CHF 372 800 | 48 months | KFS-6718-02-2026-R

Seifert Robert | Integrating Spatial Transcriptomics with Matched Patient-Derived Organoid Models for Target Identification and Preclinical Evaluation of Radioligand Therapies in Pancreatic Ductal Adenocarcinoma

Nuclear Medicine, Inselspital Bern, Bern

CHF 359 815 | 48 months | KFS-6682-02-2026-R

Clinical Research – patient-oriented

Fusi-Schmidhauser Tanja | Effectiveness of virtual reality for the management of pain in palliative care cancer patients – A multicentric randomized controlled trial

Palliative and Supportive Care Clinic, Ente Ospedaliero Cantonale (EOC), Bellinzona
CHF 374 230 | 48 months | KFS-6646-02-2026

Gillessen Silke | FREEZE-PC: efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms in patients with prostate cancer receiving androgen deprivation therapy, an investigator-initiated placebo controlled randomized trial (E Ospedale San Giovanni, Medical Oncology, Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona

CHF 340 127 | 36 months | KFS-6683-02-2026

Heidinger Martin | Impact of adjunctive mesh on quality of life and satisfaction in patients undergoing implant-based breast reconstruction following mastectomy for treatment or prevention of breast cancer: A pragmatic, international, multicenter, randomized trial (OPBC/MES

Breast Surgery, Universitätsspital Basel (USB), Basel
CHF 373 840 | 48 months | KFS-6694-02-2026

Joerger Markus | Prospective clinical trial on immune-mediated reproductive disorders in melanoma patients receiving PD(L)1/CTLA4/LAG3-targeted systemic treatment

Departement Onkologie/Hämatologie, HOCH Health Ostschweiz, St. Gallen
CHF 278 807 | 36 months | KFS-6643-02-2026

Özdemir Berna | MELCHRONO: A prospective randomized study investigating chrono-immunotherapy for advanced melanoma

Oncology, Inselspital Bern, Bern
CHF 372 642 | 48 months | KFS-6635-02-2026

Schucht Philippe | RESURGE – Multicentre Randomized Controlled Comparative Phase II Trial on Surgery for Glioblastoma Recurrence

Department of Neurosurgery, Universität Bern (UniBE), Bern
CHF 337 056 | 36 months | KFS-6645-02-2026

von Strauss und Torney Marco | Research on effective strategies after immunotherapy for mismatch repair-deficient early-stage GI tumors – RESIST study.

Chirurgie, Clarunis AG, Basel
CHF 150 744 | 48 months | KFS-6686-02-2026

Epidemiological research

Imbimbo Martina | A Real-World and Synthetic Control Infrastructure for Hybrid Trials in Thymic Epithelial Tumors

Oncology, Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona

CHF 195 354 | 24 months | KFS-6638-02-2026

Latzin Philipp | Characterising exercise performance in childhood cancer survivors: a multicentre study

Departement Klinische Forschung, Inselspital Bern, Bern

CHF 374 597 | 36 months | KFS-6728-02-2026

Meyer Jeremy | Missed Opportunities for Ovarian Cancer Prevention During Digestive Surgery: A Nationwide Epidemiological Study

Service de chirurgie viscérale, Hôpitaux universitaires de Genève (HUG), Genève

CHF 289 563 | 36 months | KFS-6636-02-2026

Health services research

Kröll Dino | Provider Volume, care structures, and long-term Outcomes of Multimodal Treatment for Oesophageal and Gastric cancer in Switzerland: A Population-Based Study

Visceral Surgery and Medicine, Inselspital Bern, Bern

CHF 69 335 | 18 months | KFS-6734-02-2026

Psychosocial research

Lelorain Sophie | Physician Empathy During Diagnosis and Treatment Change in Advanced Cancer: Determinants and Impact

Institut de Psychologie, Université de Lausanne (UNIL), Lausanne

CHF 356 130 | 48 months | KFS-6670-02-2026-R

Fellowships

Eller Ruth Stefanie | SPARC-OCS - Systematic Precision Analysis of Rare Cancers - Ovarian Carcinosarcoma: Identifying drivers of aggressiveness and potential therapeutic targets

Gynecologic Oncology, Universitätsspital Basel (USB), Basel

CHF 126 000 | 24 months | KFS-6719-02-2026 BIL

Marconato Maddalena | Targeting IL-1 to Limit Emergency Myelopoiesis (EM) and Prevent Lung Cancer: A Translational Project Embedded in a Phase II Trial of Nadunolimab in Patients with High-Risk Pulmonary Nodules

Medical Oncology and Hematology, Universitätsspital Zürich (USZ), Zürich

CHF 157 500 | 24 months | KFS-6709-02-2026 BIL

Schimmer Roman | Clonal evolution and therapeutic vulnerabilities in complex karyotype myeloid neoplasms

Klinik für medizinische Onkologie und Hämatologie, Universitätsspital Zürich (USZ), Zürich

CHF 196 550 | 24 months | KFS-6615-02-2026 BIL